Pancreatic Fistula After Minimally Invasive Enucleation

Minimally invasive enucleation (MIEN) has been widely used in managing benign and low-grade malignant pancreatic tumors, showing better protection of pancreatic function and better long-term outcomes compared to standard pancreatectomy.

However, the incidence of postoperative pancreatic fistula (POPF) after MIEN is higher compared to standard resection, mainly since a large part of the pancreatic wound is exposed, and the main pancreatic duct may be exposed or injured, etc. POPF is the most important postoperative complication, and it has become a major constraint to the conduct of pancreatic MIEN.

Although risk factors and predictive models for POPF in standard pancreatic surgery have been reported in the past, no predictive models have been reported specifically for MEN. With the increasing adoption of MIEN, there is an urgent need for a predictive model to guide the treatment and prognosis of POPF. Therefore, this study aims to conduct a cohort study, with data prospectively collected and retrospectively analyzed. The result of this study will provide a valuable reference for the development and application of MIEN.

Inclusion criteria

• Age between 18 and 70 years, regardless of gender.
• Benign or low-grade malignant tumor of the pancreas.
• Patients evaluated according to guidelines that indicate a need for surgery or a strong request for surgery.
• Feasibility of performing minimally invasive pancreatic tumor enucleation based on preoperative imaging evaluation.
• Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Willingness to comply with the follow-up programme of the study and other protocol requirements.
• Voluntary participation and signed informed consent.

Exclusion criteria

• Concurrent presence of other malignant tumors.
• Intraoperative frozen pathology or postoperative pathology indicating the tumor to be malignant, requiring oncological resection instead.
• Severe impairment of cardiac, hepatic, or renal function (e.g., NYHA class 3-4 heart failure, ALT and/or AST levels exceeding three times the upper limit of normal, creatinine levels exceeding the upper limit of normal).
• Missing data due to patient loss of followup, etc.